-
公开(公告)号:US07285551B2
公开(公告)日:2007-10-23
申请号:US10615329
申请日:2003-07-08
IPC分类号: A61K31/50 , A61K31/4965 , A01N43/54 , C07D239/42 , C07D401/04
CPC分类号: C07D231/12 , A61K31/4184 , A61K31/42 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4523 , A61K31/496 , A61K31/519 , A61K31/52 , A61K31/53 , A61K31/55 , A61K31/7076 , A61K38/21 , A61K45/06 , C07D209/12 , C07D233/56 , C07D235/18 , C07D235/30 , C07D249/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/10 , C07D417/12 , C07D417/14 , C07D419/12 , C07D471/04 , C07D495/04 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , A61K2300/00
摘要: The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hepatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
摘要翻译: 本发明提供下述通式[I]的稠环化合物,其中各符号如说明书中所定义,其药学上可接受的盐和含有该化合物的丙型肝炎治疗剂。 本发明化合物基于HCV聚合酶抑制活性显示抗丙型肝炎病毒(HCV)作用,可用作丙型肝炎的治疗剂或预防剂。
-
公开(公告)号:US20070032497A1
公开(公告)日:2007-02-08
申请号:US11093208
申请日:2005-03-28
IPC分类号: A61K31/522 , A61K31/519 , A61K31/498 , A61K31/503 , A61K31/4745 , A61K31/404 , A61K31/4184
CPC分类号: C07D231/12 , A61K9/2018 , A61K31/404 , A61K31/4184 , A61K31/42 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4523 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/503 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/53 , A61K31/55 , A61K31/7076 , C07D233/56 , C07D235/18 , C07D235/30 , C07D249/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D495/04
摘要: The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
摘要翻译: 本发明提供下述通式[I]的稠环化合物,其中各符号如说明书中所定义,其药学上可接受的盐和含有该化合物的丙型肝炎治疗剂。 本发明化合物基于HCV聚合酶抑制活性显示抗丙型肝炎病毒(HCV)作用,可用作丙型肝炎的治疗剂或预防剂。
-
公开(公告)号:US20050070545A1
公开(公告)日:2005-03-31
申请号:US10913307
申请日:2004-08-06
申请人: Brian Fox , Kiyosei Iio , Takashi Inaba , Frank Kayser , Kexue Li , Shoichi Sagawa , Masahiro Tanaka , Atsuhito Yoshida
发明人: Brian Fox , Kiyosei Iio , Takashi Inaba , Frank Kayser , Kexue Li , Shoichi Sagawa , Masahiro Tanaka , Atsuhito Yoshida
IPC分类号: A01N43/58 , A01N43/60 , A61K20060101 , A61K31/495 , A61K31/50 , A61K31/503 , A61K31/535 , C07D237/26 , C07D237/28 , C07D413/00 , C07D487/00 , C07D487/04
CPC分类号: C07D487/04
摘要: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
摘要翻译: 本文提供了可用于治疗或预防代谢和细胞增殖性疾病或病症的化合物,药物组合物和方法。 特别地,本发明提供调节参与脂质代谢和细胞增殖的蛋白质的活性的化合物。
-
公开(公告)号:US06770666B2
公开(公告)日:2004-08-03
申请号:US09939374
申请日:2001-08-24
IPC分类号: C07D20912
CPC分类号: C07D231/12 , A61K31/4184 , A61K31/42 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4523 , A61K31/496 , A61K31/519 , A61K31/52 , A61K31/53 , A61K31/55 , A61K31/7076 , A61K38/21 , A61K45/06 , C07D209/12 , C07D233/56 , C07D235/18 , C07D235/30 , C07D249/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/10 , C07D417/12 , C07D417/14 , C07D419/12 , C07D471/04 , C07D495/04 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , A61K2300/00
摘要: The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hepatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
摘要翻译: 本发明提供下述通式[I]的稠环化合物,其中各符号如说明书中所定义,其药学上可接受的盐和含有该化合物的丙型肝炎治疗剂。 本发明化合物基于HCV聚合酶抑制活性显示抗丙型肝炎病毒(HCV)作用,可用作丙型肝炎的治疗剂或预防剂。
-
公开(公告)号:US07244727B2
公开(公告)日:2007-07-17
申请号:US10720844
申请日:2003-11-21
申请人: Brian M. Fox , Noboru Furukawa , Xiaolin Hao , Kiyosei Iio , Takashi Inaba , Simon M. Jackson , Frank Kayser , Marc Labelle , Kexue Li , Takuya Matsui , Dustin L. McMinn , Nobuya Ogawa , Steven M. Rubenstein , Shoichi Sagawa , Kazuyuki Sugimoto , Masahiro Suzuki , Masahiro Tanaka , Guosen Ye , Atsuhito Yoshida , Jian Zhang
发明人: Brian M. Fox , Noboru Furukawa , Xiaolin Hao , Kiyosei Iio , Takashi Inaba , Simon M. Jackson , Frank Kayser , Marc Labelle , Kexue Li , Takuya Matsui , Dustin L. McMinn , Nobuya Ogawa , Steven M. Rubenstein , Shoichi Sagawa , Kazuyuki Sugimoto , Masahiro Suzuki , Masahiro Tanaka , Guosen Ye , Atsuhito Yoshida , Jian Zhang
IPC分类号: C07D498/04 , A61K31/542 , A61P3/04 , A61P3/08 , C07D491/04 , C07D495/04 , A61K31/538 , A61K31/519
CPC分类号: C07D491/04
摘要: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
摘要翻译: 本文提供了可用于治疗或预防代谢和细胞增殖性疾病或病症的化合物,药物组合物和方法。 特别地,本发明提供调节参与脂质代谢和细胞增殖的蛋白质的活性的化合物。
-
公开(公告)号:US07112600B1
公开(公告)日:2006-09-26
申请号:US10180558
申请日:2002-06-26
IPC分类号: A01N43/50 , C07D235/04 , C07D401/00 , C07D405/14 , A81K31/418
CPC分类号: C07D231/12 , A61K9/2018 , A61K31/404 , A61K31/4184 , A61K31/42 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4523 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/503 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/53 , A61K31/55 , A61K31/7076 , C07D233/56 , C07D235/18 , C07D235/30 , C07D249/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D495/04
摘要: The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hepatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
摘要翻译: 本发明提供下述通式[I]的稠环化合物,其中各符号如说明书中所定义,其药学上可接受的盐和含有该化合物的丙型肝炎治疗剂。 本发明化合物基于HCV聚合酶抑制活性显示抗丙型肝炎病毒(HCV)作用,可用作丙型肝炎的治疗剂或预防剂。
-
公开(公告)号:US07300932B2
公开(公告)日:2007-11-27
申请号:US10913307
申请日:2004-08-06
申请人: Brian M. Fox , Kiyosei Iio , Takashi Inaba , Frank Kayser , Kexue Li , Shoichi Sagawa , Masahiro Tanaka , Atsuhito Yoshida
发明人: Brian M. Fox , Kiyosei Iio , Takashi Inaba , Frank Kayser , Kexue Li , Shoichi Sagawa , Masahiro Tanaka , Atsuhito Yoshida
IPC分类号: C07D487/04 , A61K31/5025
CPC分类号: C07D487/04
摘要: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
摘要翻译: 本文提供了可用于治疗或预防代谢和细胞增殖性疾病或病症的化合物,药物组合物和方法。 特别地,本发明提供调节参与脂质代谢和细胞增殖的蛋白质的活性的化合物。
-
公开(公告)号:US20070244096A1
公开(公告)日:2007-10-18
申请号:US11743376
申请日:2007-05-02
申请人: Brian Fox , Noboru Furukawa , Xiaolin Hao , Kiyosei Iio , Takashi Inaba , Simon Jackson , Frank Kayser , Marc Labelle , Kexue Li , Takuya Matsui , Dustin McMinn , Nobuya Ogawa , Steven Rubenstein , Shoichi Sagawa , Kazuyuki Sugimoto , Masahiro Suzuki , Masahiro Tanaka , Guosen Ye , Atsuhito Yoshida , Jian Zhang
发明人: Brian Fox , Noboru Furukawa , Xiaolin Hao , Kiyosei Iio , Takashi Inaba , Simon Jackson , Frank Kayser , Marc Labelle , Kexue Li , Takuya Matsui , Dustin McMinn , Nobuya Ogawa , Steven Rubenstein , Shoichi Sagawa , Kazuyuki Sugimoto , Masahiro Suzuki , Masahiro Tanaka , Guosen Ye , Atsuhito Yoshida , Jian Zhang
IPC分类号: A61K31/55 , A61K31/542 , A61K31/5383 , C07D497/02 , C07D498/02 , C07D491/02
CPC分类号: C07D491/04
摘要: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
摘要翻译: 本文提供了可用于治疗或预防代谢和细胞增殖性疾病或病症的化合物,药物组合物和方法。 特别地,本发明提供调节参与脂质代谢和细胞增殖的蛋白质的活性的化合物。
-
-
-
-
-
-
-